Following detection of high levels of serum prostate-specific antigen, many men are advised
to have transrectal ultrasound-guided biopsy in an attempt to locate a cancer. This …

The accurate identification and stratified treatment of clinically significant early-stage
prostate cancer have been ongoing concerns since the outcomes of large international …

Importance Overdiagnosis and overtreatment of indolent prostate cancer (PCA) is a serious
health issue in most developed countries. There is an unmet clinical need for noninvasive …

Background To reduce overdiagnosis and overtreatment, a test is urgently needed to detect
clinically significant prostate cancer (PCa). Objective To develop a multimodal model …

Background: New screening methods that can add predictive diagnostic value for
aggressive (high-grade, Gleason score⩾ 7) prostate cancer (PCa) are needed to reduce …

Importance Potential survival benefits from treating aggressive (Gleason score,≥ 7) early-
stage prostate cancer are undermined by harms from unnecessary prostate biopsy and …

Purpose: Given the limitations of prostate specific antigen and standard biopsies for
detecting prostate cancer, we evaluated the cancer detection rate and external validity of a …

This review discusses the most recent evidence for currently available risk stratification tools
in the detection of clinically significant prostate cancer (csPCa), and evaluates diagnostic …

Prostate cancer screening and diagnosis has been guided by prostate-specific antigen
levels for the past 25 years, but with the most recent US Preventive Services Task Force …

Prostate cancer remains the most commonly diagnosed noncutaneous malignancy among
Canadian men and is the third leading cause of cancer-related death. In 2016, an estimated …